1. Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, et al. Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study. Clin Ther 2017;39:759-770.
[CROSSREF] [PUBMED]
2. Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008;14(5 Suppl B):S2-S19.
[CROSSREF]
3. Tran L, Zielinski A, Roach AH, Jende JA, Householder AM, Cole EE, et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother 2015;49:540-556.
[CROSSREF] [PUBMED]
4. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
[CROSSREF] [PUBMED]
5. Grey A, Bolland M, Fenwick S, Horne A, Gamble G, Drury PL, et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 2013;170:255-262.
[CROSSREF] [PUBMED]
6. Kahn BB, McGraw TE. Rosiglitazone, PPARγ, and type 2 diabetes. N Engl J Med 2010;363:2667-2669.
[CROSSREF] [PUBMED] [PMC]
7. Ksiazek K. A comprehensive review on mesenchymal stem cell growth and senescence. Rejuvenation Res 2009;12:105-116.
[CROSSREF] [PUBMED]
8. Wan Y. PPARγ in bone homeostasis. Trends Endocrinol Metab 2010;21:722-728.
[CROSSREF] [PUBMED]
9. Patel JJ, Butters OR, Arnett TR. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem Funct 2014;32:368-377.
[CROSSREF] [PUBMED]
10. Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015;58:2238-2246.
[CROSSREF] [PUBMED] [PDF]
11. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-1235.
[CROSSREF] [PUBMED] [PDF]
12. Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:1519-1528.
[CROSSREF] [PUBMED] [PDF]
13. Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res 2015;30:481-488.
[CROSSREF] [PUBMED] [PMC]
14. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006;38:74-84.
[CROSSREF] [PUBMED]
15. Liu C, Feng T, Zhu N, Liu P, Han X, Chen M, et al. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Sci Rep 2015;5:9530
[CROSSREF] [PUBMED] [PMC]
16. Sellmeyer DE, Civitelli R, Hofbauer LC, Khosla S, Lecka-Czernik B, Schwartz AV. Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes. Diabetes 2016;65:1757-1766.
[CROSSREF] [PUBMED] [PMC]
17. Schwartz AV. Diabetes, bone and glucose-lowering agents: clinical outcomes. Diabetologia 2017;60:1170-1179.
[CROSSREF] [PUBMED] [PDF]
18. Bae KH, Seo JB, Jung YA, Seo HY, Kang SH, Jeon HJ, et al. Lobeglitazone, a novel peroxisome proliferator-activated receptor γ agonist, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice. Endocrinol Metab (Seoul) 2017;32:115-123.
[CROSSREF] [PUBMED] [PMC]
19. Osman I, Segar L. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. Biochem Pharmacol 2016;101:54-70.
[CROSSREF] [PUBMED]
20. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331.
[CROSSREF] [PUBMED] [PMC]
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-1289.
[CROSSREF] [PUBMED]
22. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-215.
[CROSSREF] [PUBMED]
23. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-355.
[CROSSREF] [PUBMED] [PDF]
24. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008;473:201-209.
[CROSSREF] [PUBMED]
25. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone 2009;44:1026-1033.
[CROSSREF] [PUBMED]
26. Crossno JT Jr, Majka SM, Grazia T, Gill RG, Klemm DJ. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 2006;116:3220-3228.
[CROSSREF] [PUBMED] [PMC]
27. Berberoglu Z, Yazici AC, Demirag NG. Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf) 2010;73:305-312.
[CROSSREF] [PUBMED]
28. Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013;98:4691-4701.
[CROSSREF] [PUBMED]
29. Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, et al. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2015;52:1083-1091.
[CROSSREF] [PUBMED] [PDF]
30. Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, Shin JS, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 2005;40:862-874.
[CROSSREF] [PUBMED]
31. Kim BY, Ahn JB, Lee HW, Kang SK, Lee JH, Shin JS, et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem 2004;39:433-447.
[CROSSREF] [PUBMED]
32. Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, Ko KS, et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One 2014;9:e92843
[CROSSREF] [PUBMED] [PMC]
33. Kim SH, Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, et al. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study. Diabetes Res Clin Pract 2015;110:e27-e30.
[CROSSREF] [PUBMED]
34. Lim S, Lee KS, Lee JE, Park HS, Kim KM, Moon JH, et al. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 2015;243:107-119.
[CROSSREF] [PUBMED]